AVRHealthcare · Medical Instruments & SuppliesAVR Stock Forecast: Anteris Technologies Global Corp. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Anteris Technologies Global Corp. hold a median 12-month price target of $15 — +81.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
AVR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Anteris Technologies Global Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (83): The shares have been drifting up relative to others.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Anteris Technologies Global Corp. — and when they’d sell — is the membership.
AVR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AVR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +81.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | Barclays | Maintains | Overweight | $17 → $18 |
| 27 Mar 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 12 Mar 2026 | Cantor Fitzgerald | Assumes | Overweight | $15 |
| 11 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 8 Jan 2025 | Lake Street | Initiates | Buy | — |
| 7 Jan 2025 | Barclays | Initiates | Overweight | — |
| 7 Jan 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 7 Jan 2025 | TD Cowen | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AVR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Anteris Technologies Global Corp. (AVR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.1×
- Price / sales
- 412.3×
- Price / book
- 2.7×
- EV / EBITDA
- −5.1×
Cheaper than 87% of US stocks
Cheaper than 2% of US stocks
Cheaper than 36% of US stocks
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- −11.2%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −4859.7%
- Net margin
- 0.0%
Higher than 15% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- −59.2%
- Return on assets
- −34.0%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AVR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVR appears on the weeks it earns a place.
Frequently asked questions about AVR stock
What is the AVR stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Anteris Technologies Global Corp. have a median 12-month price target of $15, with estimates ranging from $15 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AVR stock a buy right now?
Of the 3 analysts covering Anteris Technologies Global Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anteris Technologies Global Corp. 31 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AVR?
As at 1 Aug 2026, Anteris Technologies Global Corp. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).
Will AVR stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +81.2% from the last close, and Ticker Nerd's factor model ranks Anteris Technologies Global Corp. 31 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AVR stock forecast for 2030?
No analyst covering Anteris Technologies Global Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $16 over the next 12 months.
How has AVR stock performed over the past year?
Anteris Technologies Global Corp. returned +169.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Anteris Technologies Global Corp. do?
Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases.
About Anteris Technologies Global Corp.
Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases. Its flagship product, the DurAVR Transcatheter Heart Valve system, features a single-piece, native-shaped biomimetic design engineered to mimic the performance of a healthy aortic valve, addressing aortic stenosis through minimally invasive procedures. The system incorporates ADAPT anti-calcification tissue, which transforms xenograft material into durable bioscaffolds resembling human tissue, and the ComASUR delivery system, a balloon-expandable mechanism with a reinforced steerable catheter for precise navigation through heart anatomy. Anteris Technologies Ltd. operates across key markets including the United States, Germany, Australia, Switzerland, and Sweden, with a focus on advancing cardiac care via science-driven innovations. Headquartered in Toowong, Australia, the company partners with interventional cardiologists and cardiac surgeons to deliver paradigm-shifting hemodynamic performance and deliverability in transcatheter aortic valve replacement therapies.
CEO Mr. Wayne Geoffrey Paterson · 174 employees · Australia · https://anteristech.com